Moderna

Moderna ($MRNA) stock surged 130% following reports that a cancer vaccine showed signs of preventing melanoma from spreading.

Moderna $MRNA surges 130%

Moderna stock jumped 130% following a successful human trial for its skin cancer vaccine. The treatment proved effective even for late-stage melanoma patients.

Moderna skin cancer vaccine results

Moderna's mRNA flu vaccine just got a big boost. An independent FDA advisory panel unanimously recommended it for approval in older adults. The vaccine showed about 27% better efficacy than standard flu shots in clinical… Mostrar más

Moderna mRNA flu vaccine FDA panel

Three days ago someone said AI will cure cancer. Today an AI built personalized cancer vaccine passed a Phase 3 trial. Moderna and Merck sequence tumor DNA vs healthy DNA, use AI to pick mutations most likely to spark a… Mostrar más

AI melanoma vaccine Phase 3 results